Pyrrolo[2,3]pyrimidine inhibitors of Janus kinase 3 protein tyrosine kinase

Bibliography

• KAHAN B, KOCH S: Current immunosuppressant regimens: considerations for critical care. Curt: Opin. Crit. Care (2001) 7(4):242–250.
   PubMedGoogle Scholar
• LO A, ALLOWAY R: Strategies to reduce toxicities and improve outcomes in renal transplant recipients. Phannacotherapy (2002) 22(3):316–328.
   PubMed Web of Science ®Google Scholar
• CRABTREE G: Calcium, calcineurin, and the control of transcription. Biol. Chem. (2001) 276(4):2313–2316.
   Web of Science ®Google Scholar
• JORGENSEN K, KOEFOED-NIELSEN P, KARAMPERIS N: Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scan. Immunol (2003) 57(2):93–98.
   Google Scholar
• KAHAN B, MAHALATI K: Clinical pharmacokinetics of sirolimus. Pharmacokinetics (2001) 40(8):573–585.
   PubMed Web of Science ®Google Scholar
• WIEDERRECHT G, SABERS C, BRUNN G et al.: Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Avg. Cell Cycle Res. (1995) 1:53–71.
   PubMedGoogle Scholar
• ALLISON A, EUGUI E: Mycophenolate mofetil and its mechanism of action. Immunopharmacology (2000) 47:85–118.
   PubMed Web of Science ®Google Scholar
• •A review of how an inhibitor of purine biosynthesis can act specifically on T cells.
   Google Scholar
• QUIROZ Y, HERRERA-ACOSTA J, JOHNSON R, RODRIGUEZ-ITURBE B: Mycophenolate mofetil treatment in conditions different from organ transplantation. Transplantation Proc. (2002) 34(7):2523–2526.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, LYNCH K: FTY720: targeting G-protein-coupled receptors for sphingosine-l-phosphate in transplantation and autoimmunity. Can: Opin. Immunol (2002) 14:569–575.
   Google Scholar
• MANDALA S, HADJU R, BERGSTROM J et al.: Alteration of lymphocyte trafficking by sphingosine-l-phosphate receptor agonists. Science (2002) 296(5566):346–349.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, MARCEN R, ORTUNO J: Anti-interleultin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial. Transplantation (2001) 16(9):1756–1760.
   PubMed Web of Science ®Google Scholar
• VIAL T, CHOQUET-KASTYLEVSKY G, DESCOTES J: Adverse effects of immunotherapeutics involving the immune system. Toxicology (2002) 174:3–11.
   PubMed Web of Science ®Google Scholar
• OLYAEI J, DEMATTOS A, BENNETT W: Nephrotoxicity in immunosuppressive drugs: new insight and preventive strategies. Curc Opin. Crit. Care (2001) 7:384–389.
   PubMedGoogle Scholar
• RUDGE P, KOETSIER J, MERTIN J et al: Randomised double-blind controlled trial of cyclosporine in multiple sclerosis.' Neurol Neurosurgery and Psychiatry (1989) 52(7):932.
   Google Scholar
• GOLDBLUM R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol (1993) 11(S8):S117–119.
   PubMed Web of Science ®Google Scholar
• Physicians Desk Reference. Sifton DW (Ed.), Thomson PDR, Montvale NJ, USA (2003).
   Google Scholar
• THOMIS D, BERG L: The role of JAK3 in lymphoid development, activation, and signaling. Can: Opin. Immunol (1997) 9(4):541–547.
   PubMed Web of Science ®Google Scholar
• •Thoroughly reviews the multiple factors contributing to jak3-deficient irnmunocompromise in mice.
   Google Scholar
• O'SHEA JJ: JAKs, STATs, cytoldne signal transduction, and immunoregulation: are we there yet? Immunity (1997) 7:1–11.
   Google Scholar
• NOTARANGELO L, GILIANI S, MAZZA C et al: Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the 7 (c)-JAK3 signaling pathway as a model. Immunol Rev. (2000) 178:39–48.
   Google Scholar
• MACCHI P, VILLA A, GILLANI S et al.:Mutations of Jak-3 gene in patients with autosomal severe combined immune defiency (SCID). Nature (1995) 377:65–68.
   PubMed Web of Science ®Google Scholar
• CETKOVIC-CVRLJIE M, DRAGT A, VASSILEV A, LIU X, UCKUN F: Targeting JAK3 with JANEX-1 for prevention of autoimmune Type 1 diabetes in NOD mice. Clin. Immunol (2003) 106(3):213–225.
   PubMed Web of Science ®Google Scholar
• SUDBECK E, LIU X, NARLA RK et al: Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. (1999) 5(6):1569–1582.
   PubMed Web of Science ®Google Scholar
• MEYDAN N, GRUNBERGERT, DADI H et al.: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 379(6566):645–648.
   PubMed Web of Science ®Google Scholar
• THOMPSON J, CUBBON R, CUMMINGS R et al.: Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor. Bioorg. Med. Chem. Lett. (2002) 12:1219–1223.
   PubMed Web of Science ®Google Scholar
• STEPKOWSKI S, ERWIN-COHEN R, BEHBOD F et al.: Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporin but additively with rapamycin. Blood (2002) 99:680–689.
   PubMed Web of Science ®Google Scholar
• VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291(5507):304–1351.
   Web of Science ®Google Scholar
• WILLIAMS D, MITCHELL T: Latest developments in crystallography and structure-based drug design of protein kinase inhibitors as drug candidates. Curt: Opin. Phannacol (2002) 2:1–7.
   Web of Science ®Google Scholar
• LAWRENCE DS, NIU J: Protein kinase inhibitors: the tyrosine specific protein kinases. Pharainacol Therap. (1998) 77(2):81–114.
   PubMed Web of Science ®Google Scholar
• DAVIES S, REDDY H, CAIVANO M, COHEN P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochein. (2000) 351(Pt 1):95–105.
   PubMed Web of Science ®Google Scholar
• ••A critical evaluation of kinase inhibitorsclaimed to be specific, many of which are shown not to be so.
   Google Scholar
• DRUKER B: 5TI571(Gleevec) as a paradigmfor cancer therapy,. Trends in Ma Med. (2002) 8(4):514–518.
   Web of Science ®Google Scholar
• PARGANAS E, WENG D, STRAVOPODIS D et al: JAK2 is essential for signaling through a variety of cytokine receptors. Ceil (1998) 93:385–395.
   PubMed Web of Science ®Google Scholar
• RODIG SJ, MERAZ MA, WHITE JM et al: Disruption of the JAK1 gene demonstrates obligatory and non-redundant roles of the JAKs in cytokine-induced biologic responses. Cell (1998) 93(3):373–383.
   PubMed Web of Science ®Google Scholar
• SEXL V, KOVACIC B, PIEKORZ R et al:Jakl deficiency leads to enhanced Abelson-induced B-cell tumor deficiency. Blood (2003) 101(12):4937–4943
   PubMed Web of Science ®Google Scholar